ORGO - Organogenesis Holdings Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.7000
-0.1700 (-3.49%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.8700
Open4.8600
Bid0.0000 x 1400
Ask0.0000 x 800
Day's Range4.6600 - 4.9250
52 Week Range3.5600 - 310.9000
Volume216,628
Avg. Volume128,806
Market Cap488M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.5240
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.67
  • GlobeNewswire

    Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock

    Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the pricing of an underwritten public offering of 9,000,000 shares of its Class A common stock, offered at a price to the public of $5.00 per share. The gross proceeds to Organogenesis Holdings from this offering are expected to be $45.0 million, before deducting the underwriting discounts and commissions and other offering expenses payable by Organogenesis Holdings. Organogenesis Holdings has granted the underwriters a 30-day option to purchase up to an aggregate of 1,350,000 additional shares of its Class A common stock.

  • Benzinga

    The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...

  • GlobeNewswire

    Organogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock

    Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it is offering to sell 9,000,000 shares of its Class A common stock in an underwritten public offering. In addition, Organogenesis Holdings intends to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of its Class A common stock at the public offering price, less the underwriting discounts and commissions. Credit Suisse Securities (USA) LLC and SVB Leerink LLC are acting as joint book-running managers of the offering and BTIG, LLC and Oppenheimer & Co. Inc. are acting as co-managers for the offering.

  • GlobeNewswire

    Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results

    CANTON, Mass., Nov. 12, 2019 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and.

  • Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

  • GlobeNewswire

    Latest Advanced Wound Care Research from Organogenesis Highlighted at SAWC Fall 2019

    CANTON, Mass. and LAS VEGAS, Oct. 11, 2019 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and.

  • GlobeNewswire

    New ReNu® Data from Organogenesis Highlighted at ICRS 2019 World Congress

    CANTON, Mass. and VANCOUVER, British Columbia, Oct. 05, 2019 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development,.

  • GlobeNewswire

    Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2019 Financial Results on November 12, 2019

    Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2019 financial results will be reported after the market closes on Tuesday, November 12.

  • Largest Insider Trades of the Week
    GuruFocus.com

    Largest Insider Trades of the Week

    Insiders dump shares of Facebook, Snap Continue reading...

  • GlobeNewswire

    MEDIA ALERT: Organogenesis Holdings Inc. (Nasdaq: ORGO) to Ring the Nasdaq Stock Market Closing Bell

    NEW YORK, Sept. 06, 2019 -- What:Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company, will visit the Nasdaq MarketSite in Times Square. In.

  • GlobeNewswire

    Organogenesis Announces Annual College Scholarship Award Winner

    CANTON, Mass., Sept. 06, 2019 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and.

  • GlobeNewswire

    Organogenesis Announces Completion of Exchange Offer and Plan to Exchange Remaining Outstanding Public Warrants

    Organogenesis Holdings Inc. (ORGO) (the “Company”) announced today the completion of its previously announced exchange offer (the “Offer”) and consent solicitation relating to its publicly traded warrants. On August 19, 2019, the Company accepted all 29,950,150 publicly traded warrants tendered, representing approximately 97% of the total public warrants outstanding, and expects to issue an aggregate of 2,845,280 shares of Class A common stock (“Common Stock”) in exchange. The Company also executed an amendment to the warrant agreement governing its outstanding public warrants and expects to exchange all remaining untendered public warrants on September 3, 2019 in exchange for approximately 80,422 shares of Common Stock (the “Redemption”).

  • Organogenesis Holdings Inc. (ORGO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Organogenesis Holdings Inc. (ORGO) Q2 2019 Earnings Call Transcript

    ORGO earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    Organogenesis Holdings Inc. Reports Second Quarter and First Half 2019 Financial Results

    CANTON, Mass., Aug. 09, 2019 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and.

  • GlobeNewswire

    Organogenesis Holdings Commences Offer to Exchange Class A Common Stock for any and all Outstanding Public Warrants and Consent Solicitation

    Organogenesis Holdings Inc. (ORGO) (the “Company,” “we” or “our”) today announced that it has commenced an offer to exchange (“Offer to Exchange”) 0.095 shares of the Company’s Class A common stock (“Class A Common Stock”) for each outstanding Public Warrant originally issued in a registered offering, as further described below. This exchange ratio equates to approximately one share of Class A Common Stock for every 11 Public Warrants tendered. Concurrently with the offer, the Company is also soliciting consents from holders of Public Warrants to amend the Warrant Agreement governing all of the Public Warrants to permit the Company to require that each Public Warrant that is outstanding upon the closing of the Offer be converted into 0.0855 shares of Class A Common Stock, which is a ratio 10% less than the exchange ratio applicable to the Offer.

  • GlobeNewswire

    Organogenesis Announces 2019 Sponsorship of American Podiatric Medical Association Educational Programs and Annual Scientific Meeting

    Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced its 2019 sponsorship of the American Podiatric Medical Association (APMA), including support for two of the APMA’s leading educational programs: The Residency Education Resource Center (REdRC) and the Young Physicians’ Institute (YPI). Products from the Organogenesis advanced wound care portfolio will be highlighted with product demonstrations and information at the Organogenesis booth #401.

  • GlobeNewswire

    Organogenesis Joins Russell 2000®, Russell 3000® and Russell Microcap® Indexes

    Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced today that the Company has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes. The Company’s inclusion in these indexes will become effective today after the US market opens. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

  • Organogenesis Holdings Inc. (ORGO) Q1 2019 Earnings Call Transcript
    Motley Fool

    Organogenesis Holdings Inc. (ORGO) Q1 2019 Earnings Call Transcript

    ORGO earnings call for the period ending March 31, 2019.

  • GlobeNewswire

    Organogenesis Holdings Inc. Reports First Quarter 2019 Financial Results

    CANTON, Mass., May 10, 2019 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and.

  • GlobeNewswire

    Organogenesis Receives Innovative Technology Contract from Vizient

    Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced today that it has received an Innovative Technology contract from Vizient, Inc. for its portfolio of advanced wound care and surgical and sports medicine products. The contract for the Organogenesis product portfolio was based on a recommendation from hospital experts who serve on one of Vizient’s member-led councils.

  • GlobeNewswire

    Latest Wound Care Research from Organogenesis Highlighted at SAWC Spring 2019

    CANTON, Mass. and SAN ANTONIO, April 30, 2019 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and.

  • GlobeNewswire

    Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2019 Financial Results on May 10, 2019

    Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2019 financial results will be reported before the market opens on Friday, May 10. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.

  • GlobeNewswire

    Organogenesis Compliant With Nasdaq Listing Criteria

    CANTON, Mass., April 01, 2019 -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq:  ORGO), a leading regenerative medicine company focused on the development, manufacture.

  • GlobeNewswire

    Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results

    CANTON, Mass. , March 18, 2019 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and.

  • PR Newswire

    Organogenesis Holdings Inc. Announces New $100 Million Credit Agreement with Silicon Valley Bank and MidCap Financial

    CANTON, Mass., March 14, 2019 /PRNewswire/ -- Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced a new credit agreement with Silicon Valley Bank, the lead agent, and MidCap Financial. The agreement provides for a credit facility in the aggregate principal amount of $100 million, consisting of a $60 million term loan facility and a $40 million revolving credit facility.  The agreement contains customary representations, warranties, and covenants, including financial covenants, and requires achievement of certain financial milestones in order to draw the final $20 million of the term loan facility.  The proceeds from the term loan and revolving credit facility will be used for general corporate purposes and the repayment of the Company's existing credit facility and a lease with Eastward Capital Partners.